Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on … – About Your Online Magazine


AUSTIN, Texas, April 8, 2021 (GLOBE NEWSWIRE) – Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical pharmaceutical company that develops new, targeted and personalized therapies for rare and difficult-to-treat cancers, has announced that the Company will present the financial results for the first quarter of 2021 on Thursday, 22 April 2021, after the Close market. The Plus Therapeutics management team will hold a conference call and webcast at 5 pm Eastern Time to discuss financial results and provide a corporate update.

A live webcast will be available at ir.plustherapeutics.com/events

See the information below for teleconference dialing information. Callers must dial approximately 10 minutes before the call begins.

Conference dialing: 877-402-3914
International dialing: 631-865-5294
Conference ID: 3084418
Conference call name: Plus Therapeutics’ 2021 First Quarter Results Conference Call

After the live call, a replay will be available on the Company’s website under the ‘Relationship with investors’ section. The webcast will be available on the Company’s website for 90 days after the live call.

About Plus Therapeutics, Inc.

Plus Therapeutics (Nasdaq: PSTV) is a pharmaceutical company in a clinical stage whose radiotherapy portfolio is concentrated in radionuclides encapsulated in nanoliposomes for various cancer targets. Central to the company’s drug development is an exclusive nanotechnological platform designed to reformulate, distribute and market various drugs targeting rare cancers and other diseases. The platform is designed to facilitate new safe and effective delivery approaches and / or injectable drug formulations, potentially increasing safety, efficacy and convenience for patients and healthcare professionals. More information can be found at PlusTherapeutics.com and ReSPECT-Trials.com.

Cautionary statement about forward-looking statements

This press release contains certain statements that may be considered “forward-looking statements” under United States securities laws. All statements, except statements of historical facts, that deal with activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs, as will, should, would, could, or could occur in the future are forward-looking statements. Such statements are based on certain assumptions and assessments made by our management in the light of their experience and their perception of historical trends, current conditions, expected future developments and other factors that they believe to be appropriate. These statements include, without limitation, statements about: the Company’s potential to facilitate new safe and effective delivery approaches and / or injectable drug formulations, potentially increasing safety, efficacy and convenience for patients and healthcare professionals; the company’s potential to develop drug candidates currently in its product portfolio; and the Company’s potential to develop additional drugs outside its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including, but not limited to: the risk that the company will not be able to develop product candidates that can leverage the accelerated regulatory pathways of the US FDA; and the risks described under the heading “Risk factors” in the archives of the Company’s Securities and Exchange Commission, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is not able to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they were made, unless the Company is under an obligation to do so under United States federal securities laws .

Investor Contact
Peter Vozzo
Westwicke / ICR
(443) 377-4767
Peter.Vozzo@westwicke.com

Media contact
Terri Clevenger
Westwicke / ICR
(203) 856-4326
Terri.Clevenger@westwicke.com

Paula Fonseca